UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

What is the optimal duration, dose and frequency for anti-PD1 therapy of non-small cell lung cancer?

Kuah, Chii Yang; Monfries, Robert; Quartagno, Matteo; Seckl, Michael J; Ghorani, Ehsan; (2023) What is the optimal duration, dose and frequency for anti-PD1 therapy of non-small cell lung cancer? Therapeutic Advances in Medical Oncology , 15 pp. 1-13. 10.1177/17588359231210271. Green open access

[thumbnail of kuah-et-al-2023-what-is-the-optimal-duration-dose-and-frequency-for-anti-pd1-therapy-of-non-small-cell-lung-cancer.pdf]
Preview
Text
kuah-et-al-2023-what-is-the-optimal-duration-dose-and-frequency-for-anti-pd1-therapy-of-non-small-cell-lung-cancer.pdf - Published Version

Download (183kB) | Preview

Abstract

Over the past decade, immune checkpoint inhibitors (ICIs) have transformed the management of multiple malignancies including lung cancer. However, the optimal use of these agents in terms of duration, dose and administration frequency remains unknown. Focusing on anti-PD1 agents nivolumab and pembrolizumab in the context of non-small cell lung cancer, we argue that several lines of evidence suggest current administration regimens of these drugs may result in overtreatment with potentially important implications for cost, quality of life and toxicity. This review summarizes evidence for the scope to optimize anti-PD1 regimens, the limitations of existing data and potential approaches to solve these problems including with a novel multi-arm clinical trial design implemented in the recently opened REFINE-Lung study.

Type: Article
Title: What is the optimal duration, dose and frequency for anti-PD1 therapy of non-small cell lung cancer?
Location: England
Open access status: An open access version is available from UCL Discovery
DOI: 10.1177/17588359231210271
Publisher version: https://doi.org/10.1177/17588359231210271
Language: English
Additional information: © The Author(s) 2023. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/).
Keywords: checkpoint inhibitor, dose, duration, immunotherapy, non-small cell lung cancer, overtreatment
UCL classification: UCL
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Inst of Clinical Trials and Methodology
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Inst of Clinical Trials and Methodology > MRC Clinical Trials Unit at UCL
URI: https://discovery.ucl.ac.uk/id/eprint/10181989
Downloads since deposit
2Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item